Showing results (1-10 of 87) with videos related to
Sort By:
Pageof 9
Chemico-Biological Interactions|January 8, 2008
The use of PSA as biomarker in nutritional intervention studies of prostate cancerWytske M van Weerden, Fritz H SchröderNature Reviews. Cancer|June 20, 2014
Imaging preclinical tumour models: improving translational powerMarion de Jong, Jeroen Essers, Wytske M van WeerdenResearch Involvement and Engagement|September 26, 2023
Awe and anxiety for cancer cells: connecting scientists and patients in a holistic approach of metastasis researchHildert Bronkhorst, Wytske M van Weerden, Eline M Bunnik, et al.Pharmaceutics|November 2, 2019
The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical ResearchEline A M Ruigrok, Wytske M van Weerden, Julie Nonnekens, et al.Prostate Cancer and Prostatic Diseases|July 19, 2019
Correction to: Role of the DNA damage response in prostate cancer formation, progression and treatmentWenhao Zhang, Dik C van Gent, Luca Incrocci, et al.Prostate Cancer and Prostatic Diseases|June 15, 2019
Role of the DNA damage response in prostate cancer formation, progression and treatmentWenhao Zhang, Dik C van Gent, Luca Incrocci, et al.Plos One|October 27, 2010
Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell modelsRute B Marques, Natasja F Dits, Sigrun Erkens-Schulze, et al.Endocrine-Related Cancer|December 23, 2004
The TRPS1 transcription factor: androgenic regulation in prostate cancer and high expression in breast cancerGlenn T G Chang, Mila Jhamai, Wytske M van Weerden, et al.Cancer Research|November 17, 2006
TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancerKarin G Hermans, Ronald van Marion, Herman van Dekken, et al.Pageof 9